Daniel Barratt

Research Interests

Biomarkers Clinical Pharmacology and Therapeutics Pain Pharmacogenomics Cancer Biology and Clinical Oncology Immunology and Infection Musculoskeletal Health Neuroscience, Behaviour and Brain Health Surgical and Health Systems Innovation

Dr Daniel Barratt

Grant-Funded Research Fellow

School of Pharmacy and Biomedical Science

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Daniel Barratt is a mid career researcher in the Neuroimmunopharmacology Lab of Prof Mark Hutchinson (Discipline of Physiology) and member of the Clinical Pharmacogenomics and Drug Disposition Lab in the Discipline of Pharmacology. He is also a member of the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP).Dr Barratt has over 15 years of research experience in the area called "pharmacogenomics"; determining how our genes influence our individual responses to drugs, and how this can be used to better personalise treatments for improved safety and efficacy.

My current research focuses on identifying predictors and biomarkers of acute and chronic pain, analgesic response, and physical and psychological performance and resilience, in humans and livestock.

I have an extensive research background in clinical pharmacogenomics (especially opioid analgesics) and the neuroimmunogenetics of pain. In addition, I have led research integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers, for the personalised dosing of tyrosine kinase inhibitors against cancer. I have also been working collaboratively to identify common drug-related genetic variants in Aboriginal Australians to guide recommendations for personalised prescribing, on clinical pharmacology and pharmacogenetics research to guide precision medicine approaches in organ transplant, and on the clinical pharmacokinetics and pharmacogenetics of infectious disease treatments in Papua New Guinea.

Current Research Projects

  • "Biomarkers of persistent pain in livestock": Translating human biomarkers of pain into the livestock setting to predict the chronic pain of animal husbandry practices.
  • “A novel pathway to reduce the burden of chronic pain”: Determining how neuroimmune signalling pathway (NSP) (epi)genetics influence chronic postsurgical pain and establishing an improved framework for developing personalised pain treatment based on NSP biomarkers.
  • “Biomarker determinants of ketamine efficacy”: Determining pharmacokinetic and genomic determinants of ketamine efficacy in chronic pain and treatment-resistant depression.
  • “Improving the treatment of breathlessness”: Determining genetic predictors of the efficacy of sustained-release morphine in chronic refractory breathlessness.
  • “Personalised medicines for Aboriginal people”: Identifying and comparing drug-related genetic variation in Aboriginal and non-Aboriginal Australians, to ultimately guide personalised prescribing in Aboriginal people.
  • “Pharmacogenomics of mercaptopurine toxicity among paediatric ALL patients”: Determining the relationship between NUDT15 genetic deficiency and thiopurine toxicity in Aboriginal children with acute lymphoblastic leukaemia and lymphoma, and establishing a NUDT15 sequencing protocol for clinical implementation.
  • “Clinical pharmacology of infectious disease treatments in Papua New Guinea”: Identifying pharmacokinetic and genomic determinants of treatment response to enable drug therapy optimization for the PNG population.
  • “The inside story on variable tyrosine kinase inhibitor response and toxicity”: Integrating clinical and experimental pharmacokinetics, pharmacogenomics and mechanisms of drug resistance, for the personalised dosing of tyrosine kinase inhibitors (TKI).

Date Position Institution name
2020 - 2023 Internal Grant-Funded Researcher B University of Adelaide
2015 - 2019 NHMRC Postdoctoral Research Officer University of Adelaide
2011 - 2014 Research Assistant University of Adelaide

Date Institution name Country Title
University of Adelaide Australia PhD
University of Adelaide Australia BSc (Hons)

Year Citation
2025 Andriguetti, N. B., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2025). Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. British Journal of Clinical Pharmacology, 91(12), 1-10.
DOI
2025 Lascelles, B. D. X., Barratt, D., Basran, P. S., Brown, D. C., Coetzee, J. F., Gill, M., . . . Zhang, Q. (2025). Advancing outcome measure development and analytical approaches: Pain in Animals Workshop 2023. Frontiers in Pain Research, 6, 13 pages.
DOI
2025 Hutchinson, M. R., Barratt, D., Johnston, C. H., Humphries, M. A., Semmler, C., Tettamanzi, G. C., . . . Rolan, P. (2025). Biomarkers to predict, prevent, and treat persistent pain: omics. Pain, 166(11S), S103-S105.
DOI
2024 Lacagnina, M. J., Willcox, K. F., Boukelmoune, N., Bavencoffe, A., Sankaranarayanan, I., Barratt, D. T., . . . Grace, P. M. (2024). B cells drive neuropathic pain-related behaviors in mice through IgG-Fc gamma receptor signaling. Science Translational Medicine, 16(766), eadj1277-1-eadj1277-14.
DOI Scopus23 WoS23 Europe PMC34
2024 Barratt, D. T., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. A. (2024). Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.. The Pharmacogenomics Journal, 24(3), 18-1-18-8.
DOI Scopus1 WoS1 Europe PMC1
2022 Somogyi, A. A., Musolino, S. T., & Barratt, D. T. (2022). New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 50(1-2), 127-140.
DOI Scopus6 WoS6 Europe PMC4
2022 Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729.
DOI Scopus16 WoS11 Europe PMC9
2022 Kluger, M. T., Rice, D. A., Borotkanics, R., Lewis, G. N., Somogyi, A. A., Barratt, D. T., . . . McNair, P. J. (2022). Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.. Anaesthesia, 77(8), 882-891.
DOI Scopus18 WoS17 Europe PMC16
2021 Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909.
DOI Scopus21 WoS21 Europe PMC14
2021 Barratt, D. T., Sia, A. T., Tan, E. -C., & Somogyi, A. A. (2021). Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Medicine, 22(11), 2648-2660.
DOI Scopus6 WoS6 Europe PMC5
2021 Bordin Andriguetti, N., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci, 110(10), 3362-3366.
DOI Scopus5 WoS3 Europe PMC2
2021 Bordin Andriguetti, N., Van Schalkwyk, H. K., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 14(6), 2521-2531.
DOI Scopus8 WoS8 Europe PMC7
2020 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8.
DOI Scopus4 WoS6 Europe PMC2
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17.
DOI Scopus10 WoS10 Europe PMC9
2019 Somogyi, A. A., Barratt, D. T., Phillips, E. J., Moore, K., Ilyas, F., & Gabb, G. M. (2019). High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 85(9), 2163-2169.
DOI Scopus23 WoS19 Europe PMC14
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532.
DOI Scopus7 WoS7 Europe PMC7
2018 Liu, J., Mustafa, S., Barratt, D., & Hutchinson, M. (2018). Corticosterone preexposure increases NF-κB translocation and sensitizes IL-1β responses in BV2 microglia-like cells. Frontiers in Immunology, 9(JAN), 1-12.
DOI Scopus26 WoS21 Europe PMC18
2018 Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123(3), 320-326.
DOI Scopus33 WoS30 Europe PMC26
2018 Tucci, J., Pumuye, P., Helsby, N., Barratt, D., Pokeya, P., Hombhanje, F., & Somogyi, A. (2018). Pharmacogenomics in Papua New Guineans: Unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and Genomics, 28(6), 153-164.
DOI Scopus8 WoS7 Europe PMC8
2018 Rice, D., Kluger, M., McNair, P., Lewis, G., Somogyi, A., Borotkanics, R., . . . Walker, M. (2018). Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. British Journal of Anaesthesia, 121(4), 804-812.
DOI Scopus134 WoS127 Europe PMC96
2017 Barratt, D., & Somogyi, A. (2017). Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 6(S10), 1541-1557.
DOI Scopus17 WoS16
2017 Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985.
DOI Scopus22 WoS22 Europe PMC19
2016 Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466.
DOI Scopus25 WoS22 Europe PMC19
2016 Khan, M., Barratt, D., & Somogyi, A. (2016). Impact of CYP2C8∗3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 46(3), 278-287.
DOI Scopus18 WoS15 Europe PMC12
2015 Barratt, D., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. (2015). Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One, 10(9), e0137179-1-e0137179-13.
DOI Scopus25 WoS24 Europe PMC15
2015 Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127.
DOI Scopus39 WoS25 Europe PMC26
2014 Barratt, D., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L., . . . Somogyi, A. (2014). Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 24(4), 185-194.
DOI Scopus54 WoS44 Europe PMC38
2014 Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027.
DOI Scopus43 WoS41 Europe PMC38
2014 Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506.
DOI Scopus17 WoS12 Europe PMC12
2012 Grace, P., Hurley, D., Barratt, D., Tsykin, A., Watkins, L., Rolan, P., & Hutchinson, M. (2012). Harnessing pain heterogeneity and RNA transcriptome to idenitfy blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic construction injury model. Journal of Neurochemistry, 122(5), 976-994.
DOI Scopus27 WoS27 Europe PMC23
2012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
DOI Scopus48 WoS43 Europe PMC38
2008 Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670.
DOI Scopus3 WoS2
2007 Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444.
DOI Scopus302 WoS249 Europe PMC192
2006 Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690.
DOI Scopus137 WoS116 Europe PMC101
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331.
DOI Scopus49 WoS45 Europe PMC44
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229.

Year Citation
2022 Mustafa, S., Evans, S., Barry, B., Barratt, D., Wang, Y., Lin, C., . . . Hutchinson, M. R. (2022). Toll-Like Receptor 4 in Pain: Bridging Molecules-to-Cells-to-Systems.. In V. Kumar (Ed.), Toll-like Receptors in Health and Disease. Handbook of Experimental Pharmacology (Vol. 276, pp. 239-273). Springer Berlin Heidelberg.
DOI Scopus3 Europe PMC2
2016 Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
DOI

Year Citation
2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.

Year Citation
2023 Hutchinson, M., Barratt, D. T., Holmes, J., Mustafa, S., Bajic, J. E., Kolarich, D., . . . Semmler, C. (2023). From blood markers to performance prediction: New insights for athletes and beyond. Poster session presented at the meeting of BRAIN BEHAVIOR AND IMMUNITY. CO, Boulder: ACADEMIC PRESS INC ELSEVIER SCIENCE.
DOI
2020 Ferreira, D., Barratt, D., Somogyi, A., & Currow, D. (2020). Genetics of response to sustained-release morphine for chronic breathlessness - an exploratory study. Poster session presented at the meeting of EUROPEAN RESPIRATORY JOURNAL. ELECTR NETWORK: EUROPEAN RESPIRATORY SOC JOURNALS LTD.
DOI

Dr Barratt teaches within the B.HlthMedSci program.

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Co-Supervisor Pharmacokinetics and pharmacogenetic studies in perioperative medicine Doctor of Philosophy Doctorate Full Time Mr Matthew Kah Lup Ng
2022 Co-Supervisor The Human Integrated Sensor System (HISS) Challenge Doctor of Philosophy Doctorate Full Time Mr Michail Laoumtzis

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Co-Supervisor Exploring A20 In the Context of Neuroimmune Regulation and Pain. Doctor of Philosophy Doctorate Part Time Mr Benjamin Daniel Barry
2019 - 2023 Co-Supervisor Development and application of methods for pharmacokinetics (PK) analysis in PNG HIV/AIDS patients Doctor of Philosophy Doctorate Full Time Ms Natalia Bordin Andriguetti
2016 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu
2014 - 2015 Co-Supervisor Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib Master of Philosophy (Medical Science) Master Full Time Mr Muhammad Suleman Khan

Date Role Committee Institution Country
2016 - ongoing Member Adelaide Medical School Health Safety and Welfare Committee - -
2013 - ongoing Member ASCEPT Scientific Advisory Committee - -
2013 - ongoing Vice-Chair ASCEPT Pharmacogenomics Special Interest Group - -

Date Role Membership Country
2020 - ongoing Member International Association for the Study of Pain United States
2019 - ongoing Member Australasian Neuroscience Society Australia
2005 - ongoing Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists -

Connect With Me

External Profiles

Other Links